Litchfield Hills Research Starts Predictive Oncology (POAI) at Buy
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Investors Poured More Money Into Stocks in Past 5 Months Than Last 12 Years, Says BofA, Analysts Worried About Stretched Valuations
- Amazon.com warehouse workers vote to reject forming union in Alabama
Litchfield Hills Research initiates coverage on Predictive Oncology (NASDAQ: POAI) with a Buy rating and a price target of $3.00.
Shares of Predictive Oncology closed at $1.09 yesterday.
You May Also Be Interested In
- UPDATE: DA Davidson Starts CuriosityStream Inc. (CURI) at Buy
- UPDATE: Goldman Sachs Starts Sealed Air (SEE) at Buy
- Piper Sandler Starts US Foods (USFD) at Overweight
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!